EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment of non-... read more
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment of non-... read more
Results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression. The study, published April... read more
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce today the advancement of its breakthrough technology Cell-CT platform. The first shipment of... read more
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases,... read more
Indivior PLC (LON: INDV) today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. Reddy's, Actavis, Par, Alvogen and Teva for infringement of United States... read more